A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial
Juan Miguel Bergua Burgués(Hospital San Pedro de Alcántara), Pau Montesinos(Instituto de Salud Carlos III), Eva Barragán(Hospital Universitari i Politècnic La Fe), David Martínez‐Cuadrón(Instituto de Salud Carlos III), Ferran Vall‐Llovera Calmet(University Hospital Mútua de Terrassa), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Raquel Tarazona(Universidad de Extremadura), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Javier G. Casado(Universidad de Extremadura), Fernando Ramos(Hospital de León), Mercedes Colorado(Marqués de Valdecilla University Hospital), Evelyn Acuña‐Cruz(Hospital Universitari i Politècnic La Fe), Blanca Boluda(Hospital Universitari i Politècnic La Fe), Juan Gordillo(Universidad de Extremadura), Rosa Ayala(Hospital Universitario 12 De Octubre), Victoria Verdugo Cabeza De Vaca(Hospital Jerez Puerta del Sur), Maria Antonia Sanpol(Hospital Son Llatzer), Ignacio Casas Aviles(Hospital San Pedro de Alcántara), Marta Valero(Hospital Arnau de Vilanova), Isabel Cano(Centre Hospitalier de Versailles), Rebeca Rodriguez Veiga(Hospital Universitari i Politècnic La Fe), Antonio Garcia(Hospital Universitari Arnau de Vilanova), Joaquín Gómez Espuch(Hospital Universitario Virgen de la Arrixaca)
Cited by 1
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
|Journal of the American College of Cardiology|2013|631